4.6

CiteScore

2.2

Impact Factor
  • ISSN 1674-8301
  • CN 32-1810/R
Volume 32 Issue 6
Oct.  2018
Turn off MathJax
Article Contents
Kaibo Lin, Shikun Zhang, Jieli Chen, Ding Yang, Mengyi Zhu, Eugene Yujun Xu. Generation and functional characterization of a conditional Pumilio2 null allele[J]. The Journal of Biomedical Research, 2018, 32(6): 434-441. DOI: 10.7555/JBR.32.20170117
Citation: Kaibo Lin, Shikun Zhang, Jieli Chen, Ding Yang, Mengyi Zhu, Eugene Yujun Xu. Generation and functional characterization of a conditional Pumilio2 null allele[J]. The Journal of Biomedical Research, 2018, 32(6): 434-441. DOI: 10.7555/JBR.32.20170117

Generation and functional characterization of a conditional Pumilio2 null allele

Funds: 

We would like to thank Dr. Takeshi Kurita for discussion and assistance throughout this project. We also thank Welcome Trust Sanger Institute and Northwestern Targeting and Transgenic Core facility for assistance in the generation of mutant mice. This work was supported by National Basic Research Program of China (973 program, 2013CB945201 and 2015CB-943002)

National Science Foundation of China (81270737)

Natural Science Foundation of Jiangsu Province (BK2012838)

Provincial Innovation and Entrepreneurship Grant as well as NIH grant U01 HD045871. Funding for open access charge: Provincial Shuangchuang Program.

More Information
  • Received Date: November 06, 2017
  • Revised Date: November 27, 2017
  • The highly conserved RNA binding protein PUF (Pumilio/FBF) family is present throughout eukaryotes from yeast to mammals, with critical roles in development, fertility and the nervous system. However, the function of the mammalian PUF family members remains underexplored. Our previous study reported that a gene-trap mutation of Pum2 results in a smaller testis but does not impact fertility and viability. Although the gene-trap mutation disrupted the key functional domain of PUM protein–PUM-HD (Pumilio homology domain), but still produced a chimeric Pum2-β-geo protein containing part of PUM2, raising a question if such a chimeric protein may provide any residual function or contribute to the reproductive phenotype. Here, we report the generation of a conditional PUM2 allele, when knocked out, producing no residual PUM2 and hence a complete loss-of-function allele. We also uncovered small but significant reduction of male fertility and viability in the mutants, suggesting requirement of PUM2 for male fertility and viability
  • Cited by

    Periodical cited type(14)

    1. Najib Ullah SNM, Afzal O, Altamimi ASA, et al. Bedaquiline-Loaded Solid Lipid Nanoparticles Drug Delivery in the Management of Non-Small-Cell Lung Cancer (NSCLC). Pharmaceuticals (Basel), 2023, 16(9): 1309. DOI:10.3390/ph16091309
    2. Amrutkar CS, Patil SB. Nanocarriers for ocular drug delivery: Recent advances and future opportunities. Indian J Ophthalmol, 2023, 71(6): 2355-2366. DOI:10.4103/ijo.IJO_1893_22
    3. Gugleva V, Andonova V. Recent Progress of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Ocular Drug Delivery Platforms. Pharmaceuticals (Basel), 2023, 16(3): 474. DOI:10.3390/ph16030474
    4. Albarqi HA, Garg A, Ahmad MZ, et al. Recent Progress in Chitosan-Based Nanomedicine for Its Ocular Application in Glaucoma. Pharmaceutics, 2023, 15(2): 681. DOI:10.3390/pharmaceutics15020681
    5. Shawky S, Makled S, Awaad A, et al. Quercetin Loaded Cationic Solid Lipid Nanoparticles in a Mucoadhesive In Situ Gel-A Novel Intravesical Therapy Tackling Bladder Cancer. Pharmaceutics, 2022, 14(11): 2527. DOI:10.3390/pharmaceutics14112527
    6. Wang J, Wang H, Xu H, et al. Solid lipid nanoparticles as an effective sodium aescinate delivery system: formulation and anti-inflammatory activity. RSC Adv, 2022, 12(11): 6583-6591. DOI:10.1039/d1ra07638h
    7. Bonilla L, Espina M, Severino P, et al. Lipid Nanoparticles for the Posterior Eye Segment. Pharmaceutics, 2021, 14(1): 90. DOI:10.3390/pharmaceutics14010090
    8. Yu Z, Ding W, Aleem MT, et al. Toxoplasma gondii Proteasome Subunit Alpha Type 1 with Chitosan: A Promising Alternative to Traditional Adjuvant. Pharmaceutics, 2021, 13(5): 752. DOI:10.3390/pharmaceutics13050752
    9. González-Fernández FM, Bianchera A, Gasco P, et al. Lipid-Based Nanocarriers for Ophthalmic Administration: Towards Experimental Design Implementation. Pharmaceutics, 2021, 13(4): 447. DOI:10.3390/pharmaceutics13040447
    10. Gorantla S, Rapalli VK, Waghule T, et al. Nanocarriers for ocular drug delivery: current status and translational opportunity. RSC Adv, 2020, 10(46): 27835-27855. DOI:10.1039/d0ra04971a
    11. Chrissian C, Lin CP, Camacho E, et al. Unconventional Constituents and Shared Molecular Architecture of the Melanized Cell Wall of C. neoformans and Spore Wall of S. cerevisiae. J Fungi (Basel), 2020, 6(4): 329. DOI:10.3390/jof6040329
    12. Mahmood S, Kiong KC, Tham CS, et al. PEGylated Lipid Polymeric Nanoparticle-Encapsulated Acyclovir for In Vitro Controlled Release and Ex Vivo Gut Sac Permeation. AAPS PharmSciTech, 2020, 21(7): 285. DOI:10.1208/s12249-020-01810-0
    13. Zamboulis A, Nanaki S, Michailidou G, et al. Chitosan and its Derivatives for Ocular Delivery Formulations: Recent Advances and Developments. Polymers (Basel), 2020, 12(7): 1519. DOI:10.3390/polym12071519
    14. Jumelle C, Gholizadeh S, Annabi N, et al. Advances and limitations of drug delivery systems formulated as eye drops. J Control Release, 2020, 321: 1-22. DOI:10.1016/j.jconrel.2020.01.057

    Other cited types(0)

Catalog

    Article Metrics

    Article views (3193) PDF downloads (141) Cited by(14)
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return